IMAI is an ETH spin‑off building a 3D digital histopathology platform combining biomedicine and mechanical engineering. The company’s automated platform performs fast tissue processing, cancer detection labelling, cell counting, measuring cancer mass, and 3D visualization for clinical and research use. IMAI aims to reduce information loss and false negatives inherent in 2D histopathology and improve treatment outcomes and survival rates. It plans a two‑phase go‑to‑market: target 125 biomedical research laboratories globally by 2028, then expand into clinical pathology laboratories once medically certified. The article cites a USD 16 billion global histology and cytology market with a 15% annual growth rate from 2023–2030. IMAI will use the CHF 150,000 Venture Kick investment to scale hardware prototype capabilities, reach a design freeze, acquire customers, validate the business model, and continue developing AI features for its image analysis software. The founding team is led by co‑founders Francesca Catto (CEO), Robert Axelrod (COO), and Sascha Brun (CTO).

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024